WuXi PharmaTech, Genomics England genomics news

WuXi PharmaTech’s WuXi NextCODE subsidiary entered a contract with Genomics England to interpret genomic data from patients participating in the U.K.’s 100,000 Genomes Project. The project aims to sequence and study the genomes of 100,000 NHS England patients by 2017, with a focus on rare diseases and cancer.

NHS clinicians will use WuXi NextCODE’s sequence analysis platform to identify causative variants in rare diseases and driver mutations in cancer. WuXi NextCODE declined to disclose financial terms. ...